Patient characteristics | MTX group (n = 78) | Control group (n = 79) |
---|---|---|
Gender | ||
 Male | 42(54%) | 42(53%) |
 Female | 36(46%) | 37(47%) |
Median age, years, (range) | 34(15–63) | 34(15–62) |
MAGIC criteria grade | ||
 I-II | 74(95%) | 71(90%) |
 III-IV | 4(5%) | 8(10%) |
GVHD risk category | ||
 Standard | 75(96%) | 72(91%) |
 High | 3(4%) | 7(9%) |
Underlying malignancy | ||
 Acute myeloid leukemia | 32(41%) | 41(52%) |
 Acute lymphoid leukemia | 32(41%) | 23(29%) |
 Myelodysplastic syndrome | 11(14%) | 12(15%) |
 Other malignant disease | 3(4%) | 3(4%) |
Graft source | ||
 Peripheral blood | 68(87%) | 62(17%) |
 Bone marrow | 10(13%) | 17 (21%) |
Donor sourcea | ||
 Matched sibling donor | 6(8%) | 11(14%) |
 Matched unrelated donor | 4(5%) | 6(7%) |
 Haploidentical donor | 68(87%) | 62(79%) |
GVHD prophylaxisa | ||
 CsA + MMF + MTX | 78(100%) | 79(100%) |
Baseline organ involvement | ||
 Specific organ involved |  |  |
  Skin | 71(91%) | 65(82%) |
  Lower gastrointestinal tract or liver | 16(21%) | 25(31%) |
 Single or multi organ involvement | ||
  Single | 68(87%) | 69(87%) |
  Multi | 10(13%) | 10(13%) |